Institution
Reims University
About: Reims University is a based out in . It is known for research contribution in the topics: Population & Quality of life. The organization has 707 authors who have published 630 publications receiving 10653 citations.
Topics: Population, Quality of life, Fuzzy control system, Aneurysm, Odds ratio
Papers published on a yearly basis
Papers
More filters
••
Netherlands Cancer Institute1, The Catholic University of America2, University of Coimbra3, Mater Misericordiae University Hospital4, Memorial Sloan Kettering Cancer Center5, University College London6, Reims University7, Inje University8, Sapienza University of Rome9, Medical University of Vienna10, Karolinska University Hospital11
TL;DR: These expert consensus recommendations can be used as clinical guidelines for primary staging and restaging of rectal cancer using MRI and were constructed through consensus amongst 14 abdominal imaging experts.
Abstract: The article Magnetic resonance imaging for clinical management of rectal cancer: Updated recommendations from the 2016 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting, written by [§§§ AuthorNames §§§].
631 citations
••
Institut Gustave Roussy1, Paris Diderot University2, Odense University Hospital3, Royal Prince Alfred Hospital4, University of Tübingen5, French Institute of Health and Medical Research6, Oslo University Hospital7, Hochschule Hannover8, Reims University9, Medical University of Vienna10, Cross Cancer Institute11, University of Copenhagen12, Bristol-Myers Squibb13
TL;DR: In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival, but with increased treatment-related adverse events, while the treatment landscape for advanced melanomas has changed since this study was initiated.
Abstract: Summary Background A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3–4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit–risk profile of ipilimumab 10 mg/kg versus 3 mg/kg. Methods This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189. Findings Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6–42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9–29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6–17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9–13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70–0·99; p=0·04). The most common grade 3–4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two ( Interpretation In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment. Funding Bristol-Myers Squibb.
348 citations
••
TL;DR: In patients with LF/LGAS without CR without contractile reserve on DSE, AVR is associated with better outcome compared with medical management and surgery should not be withheld from this subset of patients solely on the basis of lack of CR.
301 citations
••
TL;DR: An easy and simple classification based on the Aachen classification is proposed for groin hernias to promote the general and systematic use for intraoperative description of the type of hernia and to increase the comparison of results in the literature.
Abstract: After reviewing the available classifications for groin hernias, the European Hernia Society (EHS) proposes an easy and simple classification based on the Aachen classification The EHS will promote the general and systematic use of this classification for intraoperative description of the type of hernia and to increase the comparison of results in the literature
278 citations
••
University of New South Wales1, French Institute of Health and Medical Research2, University Hospital of Bern3, Keio University4, Kurume University5, University of Paris6, University of Zagreb7, University at Buffalo8, Reims University9, New York University10, United States Department of Veterans Affairs11, University Medical Center Groningen12, University of Texas Southwestern Medical Center13, University of North Carolina at Chapel Hill14, University of Pennsylvania15, University of Southern California16, University of São Paulo17, University of Modena and Reggio Emilia18, Duke University19, Dresden University of Technology20, University of Barcelona21, Hokkaido University22, University of Utah23, Emory University24, Rabin Medical Center25, Memorial Medical Center26, University of California, Irvine27
TL;DR: Recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index, to assist in the development of consistent reporting of outcomes.
Abstract: Our scientific knowledge of bullous pemphigoid (BP) has dramatically progressed in recent years. However, despite the availability of various therapeutic options for the treatment of inflammatory diseases, only a few multicenter controlled trials have helped to define effective therapies in BP. A major obstacle in sharing multicenter-based evidences for therapeutic efforts is the lack of generally accepted definitions for the clinical evaluation of patients with BP. Common terms and end points of BP are needed so that experts in the field can accurately measure and assess disease extent, activity, severity, and therapeutic response, and thus facilitate and advance clinical trials. These recommendations from the International Pemphigoid Committee represent 2 years of collaborative efforts to attain mutually acceptable common definitions for BP and proposes a disease extent score, the BP Disease Area Index. These items should assist in the development of consistent reporting of outcomes in future BP reports and studies.
276 citations
Authors
Showing all 707 results
Name | H-index | Papers | Citations |
---|---|---|---|
Philippe Birembaut | 61 | 200 | 11504 |
Guillaume Cadiot | 53 | 246 | 9561 |
Alain Delmer | 49 | 260 | 8772 |
Laurent Pierot | 49 | 224 | 9748 |
Christine Clavel | 43 | 93 | 8882 |
Florent Grange | 42 | 192 | 12081 |
Philippe Gillery | 40 | 191 | 5137 |
Jacques Motte | 36 | 97 | 4974 |
Gaëtan Deslée | 30 | 180 | 2908 |
Christine Hoeffel | 30 | 172 | 3760 |
Pascale Cornillet-Lefebvre | 30 | 76 | 3424 |
Vladimir G. Tyuterev | 30 | 71 | 2207 |
Olivier Toupance | 29 | 83 | 3456 |
Damien Jolly | 28 | 116 | 2663 |
Ayman Tourbah | 28 | 114 | 5384 |